CLOZAPINE AND AGRANULOCYTOSIS: IMPACT OF THE RISK EVALUATION AND MITIGATION STRATEGY PROGRAM

被引：0
|
作者：
Borrelli, E. P. [1 ]
Lee, E. Y. [1 ]
Descoteaux, A. M. [1 ]
Caffrey, A. R. [1 ]
机构：
[1] Univ Rhode Isl, Coll Pharm, Kingston, RI 02881 USA
来源：
VALUE IN HEALTH | 2018年 / 21卷
关键词：
D O I：
10.1016/j.jval.2018.04.1228
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PMH1
引用
收藏
页码：S180 / S180
页数：1
相关论文
共 50 条
  • [41] The US Food and Drug Administration's Risk Evaluation and Mitigation Strategy (REMS) Program in Practice: Does It Really Inform Patients and Limit Risk?
    Cohen, Robert A.
    Brown, Robert S.
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2012, 59 (05) : 604 - 606
  • [42] Genetic risk factors for clozapine-induced neutropenia and agranulocytosis in a Dutch psychiatric population
    van der Weide, K.
    Loovers, H.
    Pondman, K.
    Bogers, J.
    van der Straaten, T.
    Langemeijer, E.
    Cohen, D.
    Commandeur, J.
    van der Weide, J.
    PHARMACOGENOMICS JOURNAL, 2017, 17 (05): : 471 - 478
  • [43] Genetic risk factors for clozapine-induced neutropenia and agranulocytosis in a Dutch psychiatric population
    K van der Weide
    H Loovers
    K Pondman
    J Bogers
    T van der Straaten
    E Langemeijer
    D Cohen
    J Commandeur
    J van der Weide
    The Pharmacogenomics Journal, 2017, 17 : 471 - 478
  • [44] Risk of agranulocytosis during treatment with Clozapine - patient-information in psychiatric outpatient treatment
    Haberfellner, EM
    NEUROPSYCHIATRIE, 1998, 12 (02) : 85 - 90
  • [45] CLOZAPINE-INDUCED AGRANULOCYTOSIS - INCIDENCE AND RISK-FACTORS IN THE UNITED-STATES
    ALVIR, JMJ
    LIEBERMAN, JA
    SAFFERMAN, AZ
    SCHWIMMER, JL
    SCHAAF, JA
    NEW ENGLAND JOURNAL OF MEDICINE, 1993, 329 (03): : 162 - 167
  • [46] Beyond the Label: Ensuring That Drug Benefits Outweigh Risks in the Food and Drug Administration's Risk Evaluation and Mitigation Strategy Program
    Epstein, Michael S.
    Shah, Eric D.
    Deepak, Parakkal
    Kushnir, Vladimir M.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2019, 114 (07): : 1017 - 1019
  • [47] Testing the hypothesis that selenium deficiency is a risk factor for clozapine-induced agranulocytosis in rats
    Ip, Julia
    Uetrecht, Jack P.
    CHEMICAL RESEARCH IN TOXICOLOGY, 2008, 21 (04) : 874 - 878
  • [48] Evaluation of the Incidence of Leukopenia and Agranulocytosis in Patients Receiving Combined Clozapine and Other Anti psychotics
    Akpinar, Abdullah
    Salis, Osman
    KLINIK PSIKOFARMAKOLOJI BULTENI-BULLETIN OF CLINICAL PSYCHOPHARMACOLOGY, 2012, 22 (04): : 313 - 319
  • [49] Evaluation of the Extended-Release/Long-Acting Opioid Prescribing Risk Evaluation and Mitigation Strategy Program by the US Food and Drug Administration A Review
    Heyward, James
    Olson, Lily
    Sharfstein, Joshua M.
    Stuart, Elizabeth A.
    Lurie, Peter
    Alexander, G. Caleb
    JAMA INTERNAL MEDICINE, 2020, 180 (02) : 301 - 309
  • [50] Compliance with the riociguat risk evaluation and mitigation strategies program at an academic medical center
    Riester, Melissa R.
    Greene, Rebecca A.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2020, 77 (05) : 328 - 330
12345